Somaxon was founded and incorporated in 2003.
Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Somaxon's product Silenor® (doxepin), now available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulties with sleep maintenance.
As an emerging specialty pharmaceutical company, Somaxon has not declared a cash dividend on its common stock, nor does it presently have any plans to initiate a dividend program.
Somaxon does not have a direct stock purchase program.
Somaxon's fiscal year ends on December 31st.
American Stock Transfer, which may be reached at 59 Maiden Lane, New York, NY 10038, (212) 936-5100.
Click here to request materials.
440 Stevens Avenue, Suite 200, Solana Beach, CA 92075
Somaxon's ticker symbol is SOMX and trades on the Nasdaq stock market.
Somaxon's transfer agent is American Stock Transfer, located at 59 Maiden Lane, New York, NY 10038. They may be reached at (212) 936-5100.
Click here to access a directory of our management team.
Click here to access a directory of our Board of Directors
Click here to view our Upcoming Events.
Please submit your question using the form below. * Required fields
show all
hide all
